학술논문

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Document Type
Article
Author
Attard, G.Murphy, L.Cook, A.Brawley, C.Amos, C.L.Atako, N.Pugh, C.Buckner, M.Gilson, C.Rush, H.Gilbert, D.Langley, R.E.Millman, R.Sydes, M.R.Brown, L.C.Parmar, M.K.B.Clarke, N.W.Wylie, J.Cross, W.Jones, R.J.Parker, C.C.de Bono, J.S.Dearnaley, D.P.James, N.D.Gillessen, S.Chowdhury, S.Malik, Z.Syndikus, I.Russell, J.M.Bowen, J.Lydon, A.Pedley, I.O'Sullivan, J.M.Birtle, A.Gale, J.Srihari, N.Thomas, C.Tanguay, J.Wagstaff, J.Das, P.Gray, E.Alzoueb, M.Parikh, O.Robinson, A.Zarkar, A.Thalmann, G.Mason, M.D.Matheson, D.Jones, E.Hyde, K.Glen, H.Needleman, S.McGovern, U.Sheehan, D.Paisey, S.Shaffer, R.Beresford, M.Porfiri, E.Fackrell, D.Lee, L.Sreenivasan, T.Brock, S.Brown, S.Bahl, A.Smith-Howell, M.Woodward, C.Phan, M.-D.Mazhar, D.Narahari, K.Douglas, F.Kumar, A.Hamid, A.Ibrahim, A.Muthukumar, D.Simms, M.Worlding, J.Tran, A.Kagzi, M.Pezaro, C.Sivoglo, V.Masters, B.Keng-Koh, P.Manetta, C.McLaren, D.Gupta, N.Boussios, S.Taylor, H.Graham, J.Perna, C.Melcher, L.Grant, W.Sabharwal, A.Hofmann, U.Dealey, R.McPhail, N.Brierly, R.Capaldi, L.Sidek, N.Whelan, P.Robson, P.Falconer, A.Rudman, S.Vivekanandan, S.Mullessey, V.Vilarino-Varela, M.Khoo, V.Tipples, K.Afshar, M.Brulinski, P.Sangar, V.Peedell, C.Azzabi, A.Hoskin, P.Mullassery, V.Sundar, S.Khan, Y.Conroy, R.Protheroe, A.Carser, J.Rogers, P.Tarver, K.Gibbs, S.Khan, M.M.Hingorani, M.Crabb, S.Alameddine, M.Bhalla, N.Hughes, R.Logue, J.Leaning, D.Vengalil, S.Ford, D.Walker, G.Shaheen, A.Khan, O.Chan, A.Ahmed, I.Hilman, S.Sayers, I.Nikapota, A.Bloomfield, D.Porter, T.Joseph, J.Rentsch, C.Pereira Mestre, R.Roggero, E.Beyer, J.Borner, M.Strebel, R.Berthold, D.Engeler, D.John, H.Popescu, R.Durr, D.
Source
In: The Lancet. (The Lancet, 29 January 2022, 399(10323):447-460)
Subject
Language
English
ISSN
1474547X
01406736